所属类别： 7.7mg/枚 8枚/盒
包装规格： 7.7mg/枚 8枚/盒
生产厂家英文名：Eisai Co. Ltd.
原产地英文商品名：Gliadel Implant 7.7mg/piece 8pieces/bag
英文药名：Gliadel 7.7mg Implant（Carmustine）
商标名：Gliadel 7.7mg Implant
Eyre implanted antineoplastic drugs are listed in JapanNobelpharma and Eisai’s implantable antineoplastic agent 7.7 mg Gliadel (Caramustine) was listed on Jan. 9 in Japan. Nobelpharma has completed a clinical study and obtained manufacturing and marketing rights in Japan on September 28, 2012 and was registered with the National Health Insurance (NHI) Drug List on 22 November 2012. 7.7 mg Gliadel implants were promoted by cooperation between the two companies in Japan.Gliadel in Japan is the only approved slow-release preparation for intracranial implantation. Each wafer contains bischloroethylnitrosourea, an alkylation of nitrosourea, dispersed in a biodegradable polymer matrix. Malignant glioma resection after implantation of the wafer, can make chemotherapy drugs can be directly transmitted to the tumor site.Gilladel’s significant diagnosis of newly diagnosed malignant gliomas significantly increased patient survival compared with placebo in a three-phase study conducted outside of Japan, whereas for patients with recurrent neuroblastoma after 6 months of total Survival rates also increased significantly.Gliadel has now been approved in 30 countries around the world, including the United States, Europe and Southeast Asia.Glioma is a brain tumor that accounts for 30% of all primary brain tumors. The incidence of malignant gliomas in Japan is estimated to be about 2000 to 2500 per year. Gliadel was designated as a high demand drug by the Japanese Drug Unregistered Usage Committee in September 2008 and was designated as orphan drug in June 2009.